CND Life Sciences Uses Syn-One In Ph2 Trial Parkinson’s Endpoint
11 Nov 2025 //
PR NEWSWIRE
Ablin Therapeutics Releases Phase 2 Trial Results
09 Oct 2025 //
GLOBENEWSWIRE
ABLi Therapeutics to Speak at 2025 Parkinson’s Disease Congress
15 Sep 2025 //
GLOBENEWSWIRE
ABLi Therapeutics Boosts Leadership Team and Board
28 May 2025 //
GLOBENEWSWIRE
ABLi Details FDA EOP2 Meeting On Risvodetinib For Parkinson`s
21 May 2025 //
GLOBENEWSWIRE
ABLi Launches Focus on Developing to Tackle c-Abl Neuro Diseases
12 May 2025 //
GLOBENEWSWIRE

Market Place
Sourcing Support